- Home
- YSG vs ZNTL Comparison
YSG vs ZNTL Comparison
Compare YSG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | ZNTL |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.7M | 289.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | YSG | ZNTL |
|---|---|---|
| Price | $3.30 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 103.3K | ★ 1.6M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $1.21 |
| 52 Week High | $10.59 | $6.95 |
Technical Indicators
Market Signals| Indicator | YSG | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 45.35 |
| Support Level | $3.01 | $3.53 |
| Resistance Level | $3.47 | $5.11 |
| Average True Range (ATR) | 0.25 | 0.44 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 16.81 | 5.30 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.